Partner Content Partner Content Ablation Devices Market will achieve 10%+ CAGR from 2019 to ... Ablation Devices Market will cross $25bn by 2025
News Neumora laid low by depression trial failure The first of three phase 3 trials of Neumora's novel antidepressant navacaprant has ended in failure, wreaking havoc with its share price.
Digital Sponsored The AI effect in pharma commercial strategy: From data to re... Discover how AI is transforming the pharma commercial strategy. Unlock real-time insights & actions from data. Click here for more.
